Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression

Eligibility Criteria

• * Patient has been diagnosed with diabetic peripheral neuropathy and has nerve deficit in all proposed surgical areas, sensory and/or motor
• * Patient has a positive provocative (i.e. Tinel's sign) observed clinically in the popliteal and tibial nerve trees.
• * Patient is between 18 years and 85 years of age
• * Patient is a type I or type II diabetic that is currently under medical treatment
• * Patient has a Hgb A1C lab value of 8.0% or less
• * Patient symptom based VAS scale is 6 or above for at least one of the following: pain, burning, numbness, tingling, weakness or instability
• * Patient is scheduled for surgery and has been cleared for outpatient surgery per anesthesia guidelines established for the Foot Surgery Center of Northern Colorado
• * Patient is able and willing to comply with all study requirements, including the follow-up evaluations and will return to the investigational site for all required office visits and CSU visits
• * Patient has been informed of the nature of the study, agrees to its provisions and has provided written consent
• * Patient has a BMI of greater than 40 or body weight greater than 300 pounds
• * Patient has untreated hypertension (systolic blood pressure \> 160 and/or diastolic \> 100)
• * Patient's ASA is 4 or greater
• * Patient has blood glucose greater than 200 the day of surgery
• * Patient has Raynaud's Syndrome
• * Patient is a current smoker
• * Patient is a woman who is considering pregnancy or who is pregnant
• * Patient has history of recent nerve or lumbar disc surgery, untreated thyroid disease, B12 or Folate deficiency, hepatic disease, renal disease, and/or Parkinson's disease, or neuropathy due to chemotherapy or radiation therapy
• * Patient is being treated with chemotherapeutic agents
• * Patient has ankle edema greater than mild - (Moderate to Severe)
• * Patient is participating in another investigational device, biologic, or drug study and has not completed the primary endpoint(s) or if there is a potential for clinical interference beyond the primary endpoint